Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44


Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.

Eustace AJ, Conlon NT, McDermott MSJ, Browne BC, O'Leary P, Holmes FA, Espina V, Liotta LA, O'Shaughnessy J, Gallagher C, O'Driscoll L, Rani S, Madden SF, O'Brien NA, Ginther C, Slamon D, Walsh N, Gallagher WM, Zagozdzon R, Watson WR, O'Donovan N, Crown J.

BMC Cancer. 2018 Oct 11;18(1):965. doi: 10.1186/s12885-018-4852-1.


Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer.

Konecny GE, Wang C, Hamidi H, Winterhoff B, Kalli KR, Dering J, Ginther C, Chen HW, Dowdy S, Cliby W, Gostout B, Podratz KC, Keeney G, Wang HJ, Hartmann LC, Slamon DJ, Goode EL.

J Natl Cancer Inst. 2014 Sep 30;106(10). pii: dju249. doi: 10.1093/jnci/dju249. Print 2014 Oct.


KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition.

Hamidi H, Lu M, Chau K, Anderson L, Fejzo M, Ginther C, Linnartz R, Zubel A, Slamon DJ, Finn RS.

Br J Cancer. 2014 Oct 28;111(9):1788-801. doi: 10.1038/bjc.2014.475. Epub 2014 Aug 28.


POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.

Karlan BY, Dering J, Walsh C, Orsulic S, Lester J, Anderson LA, Ginther CL, Fejzo M, Slamon D.

Gynecol Oncol. 2014 Feb;132(2):334-42. doi: 10.1016/j.ygyno.2013.12.021. Epub 2013 Dec 22.


AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53.

Kalous O, Conklin D, Desai AJ, Dering J, Goldstein J, Ginther C, Anderson L, Lu M, Kolarova T, Eckardt MA, Langerød A, Børresen-Dale AL, Slamon DJ, Finn RS.

Breast Cancer Res Treat. 2013 Oct;141(3):397-408. doi: 10.1007/s10549-013-2702-z. Epub 2013 Oct 5.


PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.

Logan JE, Mostofizadeh N, Desai AJ, VON Euw E, Conklin D, Konkankit V, Hamidi H, Eckardt M, Anderson L, Chen HW, Ginther C, Taschereau E, Bui PH, Christensen JG, Belldegrun AS, Slamon DJ, Kabbinavar FF.

Anticancer Res. 2013 Aug;33(8):2997-3004.


Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer.

Ihnen M, zu Eulenburg C, Kolarova T, Qi JW, Manivong K, Chalukya M, Dering J, Anderson L, Ginther C, Meuter A, Winterhoff B, Jones S, Velculescu VE, Venkatesan N, Rong HM, Dandekar S, Udar N, Jänicke F, Los G, Slamon DJ, Konecny GE.

Mol Cancer Ther. 2013 Jun;12(6):1002-15. doi: 10.1158/1535-7163.MCT-12-0813. Epub 2013 May 31.


Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro.

Finn RS, Aleshin A, Dering J, Yang P, Ginther C, Desai A, Zhao D, von Euw E, Busuttil RW, Slamon DJ.

Hepatology. 2013 May;57(5):1838-46. doi: 10.1002/hep.26223. Epub 2013 Apr 1.


Expression of Wnt3 activates Wnt/β-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells.

Wu Y, Ginther C, Kim J, Mosher N, Chung S, Slamon D, Vadgama JV.

Mol Cancer Res. 2012 Dec;10(12):1597-606. doi: 10.1158/1541-7786.MCR-12-0155-T. Epub 2012 Oct 15.


Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib.

Kalous O, Conklin D, Desai AJ, O'Brien NA, Ginther C, Anderson L, Cohen DJ, Britten CD, Taylor I, Christensen JG, Slamon DJ, Finn RS.

Mol Cancer Ther. 2012 Sep;11(9):1978-87. doi: 10.1158/1535-7163.MCT-11-0730. Epub 2012 Jul 3.


FOXA1 represses the molecular phenotype of basal breast cancer cells.

Bernardo GM, Bebek G, Ginther CL, Sizemore ST, Lozada KL, Miedler JD, Anderson LA, Godwin AK, Abdul-Karim FW, Slamon DJ, Keri RA.

Oncogene. 2013 Jan 31;32(5):554-63. doi: 10.1038/onc.2012.62. Epub 2012 Mar 5.


Knockdown of ovarian cancer amplification target ADRM1 leads to downregulation of GIPC1 and upregulation of RECK.

Fejzo MS, Ginther C, Dering J, Anderson L, Venkatesan N, Konecny G, Karlan B, Slamon DJ.

Genes Chromosomes Cancer. 2011 Jun;50(6):434-41. doi: 10.1002/gcc.20868. Epub 2011 Mar 22.


Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer.

Konecny GE, Winterhoff B, Kolarova T, Qi J, Manivong K, Dering J, Yang G, Chalukya M, Wang HJ, Anderson L, Kalli KR, Finn RS, Ginther C, Jones S, Velculescu VE, Riehle D, Cliby WA, Randolph S, Koehler M, Hartmann LC, Slamon DJ.

Clin Cancer Res. 2011 Mar 15;17(6):1591-602. doi: 10.1158/1078-0432.CCR-10-2307. Epub 2011 Jan 28.


Evaluation of well-differentiated/de-differentiated liposarcomas by high-resolution oligonucleotide array-based comparative genomic hybridization.

Tap WD, Eilber FC, Ginther C, Dry SM, Reese N, Barzan-Smith K, Chen HW, Wu H, Eilber FR, Slamon DJ, Anderson L.

Genes Chromosomes Cancer. 2011 Feb;50(2):95-112. doi: 10.1002/gcc.20835.


Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma.

Tap WD, Gong KW, Dering J, Tseng Y, Ginther C, Pauletti G, Glaspy JA, Essner R, Bollag G, Hirth P, Zhang C, Slamon DJ.

Neoplasia. 2010 Aug;12(8):637-49.


Periostin promotes ovarian cancer angiogenesis and metastasis.

Zhu M, Fejzo MS, Anderson L, Dering J, Ginther C, Ramos L, Gasson JC, Karlan BY, Slamon DJ.

Gynecol Oncol. 2010 Nov;119(2):337-44. doi: 10.1016/j.ygyno.2010.07.008. Epub 2010 Aug 4.


Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines.

Garon EB, Finn RS, Hosmer W, Dering J, Ginther C, Adhami S, Kamranpour N, Pitts S, Desai A, Elashoff D, French T, Smith P, Slamon DJ.

Mol Cancer Ther. 2010 Jul;9(7):1985-94. doi: 10.1158/1535-7163.MCT-10-0037. Epub 2010 Jun 29.


Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib.

O'Brien NA, Browne BC, Chow L, Wang Y, Ginther C, Arboleda J, Duffy MJ, Crown J, O'Donovan N, Slamon DJ.

Mol Cancer Ther. 2010 Jun;9(6):1489-502. doi: 10.1158/1535-7163.MCT-09-1171. Epub 2010 May 25. Erratum in: Mol Cancer Ther. 2011 Nov;10(11):2211.


RBM5/H37 tumor suppressor, located at the lung cancer hot spot 3p21.3, alters expression of genes involved in metastasis.

Oh JJ, Taschereau EO, Koegel AK, Ginther CL, Rotow JK, Isfahani KZ, Slamon DJ.

Lung Cancer. 2010 Dec;70(3):253-62. doi: 10.1016/j.lungcan.2010.02.012. Epub 2010 Mar 24.


PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.

Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, Ginther C, Atefi M, Chen I, Fowst C, Los G, Slamon DJ.

Breast Cancer Res. 2009;11(5):R77. doi: 10.1186/bcr2419.


Activity of the multikinase inhibitor dasatinib against ovarian cancer cells.

Konecny GE, Glas R, Dering J, Manivong K, Qi J, Finn RS, Yang GR, Hong KL, Ginther C, Winterhoff B, Gao G, Brugge J, Slamon DJ.

Br J Cancer. 2009 Nov 17;101(10):1699-708. doi: 10.1038/sj.bjc.6605381. Epub 2009 Oct 27.


Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target.

Fejzo MS, Dering J, Ginther C, Anderson L, Ramos L, Walsh C, Karlan B, Slamon DJ.

Genes Chromosomes Cancer. 2008 Oct;47(10):873-83. doi: 10.1002/gcc.20592.


ERCC5 is a novel biomarker of ovarian cancer prognosis.

Walsh CS, Ogawa S, Karahashi H, Scoles DR, Pavelka JC, Tran H, Miller CW, Kawamata N, Ginther C, Dering J, Sanada M, Nannya Y, Slamon DJ, Koeffler HP, Karlan BY.

J Clin Oncol. 2008 Jun 20;26(18):2952-8. doi: 10.1200/JCO.2007.13.5806.


Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells.

Konecny GE, Venkatesan N, Yang G, Dering J, Ginther C, Finn R, Rahmeh M, Fejzo MS, Toft D, Jiang SW, Slamon DJ, Podratz KC.

Br J Cancer. 2008 Mar 25;98(6):1076-84. doi: 10.1038/sj.bjc.6604278. Epub 2008 Mar 11.


Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro.

Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, Tchekmedyian N, Slamon DJ.

Breast Cancer Res Treat. 2007 Nov;105(3):319-26. Epub 2007 Feb 1.


A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers.

Bischoff JR, Anderson L, Zhu Y, Mossie K, Ng L, Souza B, Schryver B, Flanagan P, Clairvoyant F, Ginther C, Chan CS, Novotny M, Slamon DJ, Plowman GD.

EMBO J. 1998 Jun 1;17(11):3052-65.


Extent of heterogeneity in mitochondrial DNA of sub-Saharan African populations.

Melton T, Ginther C, Sensabaugh G, Soodyall H, Stoneking M.

J Forensic Sci. 1997 Jul;42(4):582-92.


DNA sequencing using a four-color confocal fluorescence capillary array scanner.

Kheterpal I, Scherer JR, Clark SM, Radhakrishnan A, Ju J, Ginther CL, Sensabaugh GF, Mathies RA.

Electrophoresis. 1996 Dec;17(12):1852-9.


Genetic variation among the Mapuche Indians from the Patagonian region of Argentina: mitochondrial DNA sequence variation and allele frequencies of several nuclear genes.

Ginther C, Corach D, Penacino GA, Rey JA, Carnese FR, Hutz MH, Anderson A, Just J, Salzano FM, King MC.

EXS. 1993;67:211-9.


Identifying individuals by sequencing mitochondrial DNA from teeth.

Ginther C, Issel-Tarver L, King MC.

Nat Genet. 1992 Oct;2(2):135-8.


Intergenic suppression of stage II sporulation defects by a mutation in the major vegetative sigma factor gene (rpoD) of Bacillus subtilis.

Lee A, Malak M, Louie P, Arjomand J, Ginther C, Leighton T.

Biochimie. 1992 Jul-Aug;74(7-8):635-40.


Roles of rpoD, spoIIF, spoIIJ, spoIIN, and sin in regulation of Bacillus subtilis stage II sporulation-specific transcription.

Louie P, Lee A, Stansmore K, Grant R, Ginther C, Leighton T.

J Bacteriol. 1992 Jun;174(11):3570-6.


Suppression of defective-sporulation phenotypes by mutations in transcription factor genes of Bacillus subtilis.

Ng C, Buchanan C, Leung A, Ginther C, Leighton T.

Biochimie. 1991 Jul-Aug;73(7-8):1163-70.


Isolation and characterization of Bacillus stearothermophilus 30S and 50S ribosomal protein mutations.

Schnier J, Gewitz HS, Behrens SE, Lee A, Ginther C, Leighton T.

J Bacteriol. 1990 Dec;172(12):7306-9.


The distribution of mutagenic activity in red, rose and white wines.

Nguyen T, Fluss L, Madej R, Ginther C, Leighton T.

Mutat Res. 1989 Jun;223(2):205-12.


Production of the cephalosporate C-2 by a Streptomyces lactamdurans mutant defective in cephamycin C biosynthesis.

Rein A, Arison B, Miller TW, Lago B, Ginther CL.

J Antibiot (Tokyo). 1984 Jun;37(6):664-6. No abstract available.


Nucleoside diphosphokinase from Salmonella typhimurium.

Ingraham JL, Ginther CL.

Methods Enzymol. 1978;51:371-5. No abstract available.


Erythromycin resistant mutations in Bacillus subtilis cause temperature sensitive sporulation.

Tipper DJ, Johnson CW, Ginther CL, Leighton T, Wittmann HG.

Mol Gen Genet. 1977 Jan 18;150(2):147-59.


Nucleoside diphosphokinase of Salmonella typhimurium.

Ginther CL, Ingraham JL.

J Biol Chem. 1974 Jun 10;249(11):3406-11. No abstract available.


Supplemental Content

Loading ...
Support Center